| アブストラクト | IMPORTANCE: Age-related macular degeneration (AMD) is the leading cause of blindness among people aged 50 years or older worldwide. There is a need for new strategies for the prevention and treatment of AMD. There is some limited evidence to suggest the possibility of a protective association of dementia medications with the development of some types of AMD, but the evidence is weak. OBJECTIVE: To investigate whether the dementia medications memantine and donepezil are associated with the risk of developing AMD. DESIGN, SETTING, AND PARTICIPANTS: Three population-based cohort studies were performed using data from the Clinical Practice Research Datalink GOLD and Aurum databases from May 15, 2002, to June 21, 2022. Participants included individuals with dementia (vascular dementia, nonvascular dementia, or Alzheimer disease) aged 40 years or older. Statistical analysis was carried out between February and November 2023. EXPOSURES: Exposures were dementia medications. Cohort 1 compared patients prescribed donepezil with those prescribed rivastigmine or galantamine using the new-user design. Cohort 2 compared memantine with donepezil, rivastigmine, or galantamine using the prevalent new-user design. In a sensitivity analysis, cohort 3 compared memantine with rivastigmine or galantamine only. MAIN OUTCOMES AND MEASURES: New diagnosis of AMD. RESULTS: There were 132 846 individuals (mean [SD] age, 80.4 [7.6] years; 61.8% women; mean [SD] body mass index [BMI], 25.5 [4.6]) with a diagnosis of dementia included in cohort 1, 159 419 individuals (mean [SD] age, 81.2 [7.6] years; 59.7% women; mean [SD] body mass index [BMI], 25.6 [4.7]) with a diagnosis of dementia included in cohort 2, and 92 328 individuals with a diagnosis of dementia included in cohort 3 (mean [SD] age, 80.9 [7.7] years; 58.5% women; mean [SD] body mass index [BMI], 25.5 [4.7]). The adjusted hazard ratio (HR) for donepezil compared with rivastigmine or galantamine (cohort 1) was 0.95 (95% CI, 0.67-1.35). The adjusted HR for memantine compared with donepezil, rivastigmine, or galantamine (cohort 2) was 1.03 (95% CI, 0.83-1.27). The adjusted HR for memantine vs rivastigmine or galantamine only (cohort 3) was 1.24 (95% CI, 0.83-1.86). CONCLUSIONS AND RELEVANCE: This cohort study of patients with dementia found no significant associations between memantine or donepezil compared with other dementia medications and the risk of development of AMD. Further research is recommended to examine any possible pathophysiological protective action of memantine and other dementia medications against the development of AMD. |
|---|
| 投稿者 | Wang, Jingya; Antza, Christina; Lee, Wen Hwa; Coker, Jesse; Keane, Pearse A; Denniston, Alastair K; Nirantharakumar, Krishnarajah; Adderley, Nicola J |
|---|
| 組織名 | Department of Applied Health Sciences, University of Birmingham, Birmingham,;United Kingdom.;Action Against Age-Related Macular Degeneration, London, United Kingdom.;NIHR (National Institute for Health and Care Research) Moorfields Biomedical;Research Centre, Moorfields Eye Hospital NHS Foundation Trust and Institute of;Ophthalmology, University College London, London, United Kingdom.;University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.;Health Data Research UK, London, United Kingdom.;NIHR Birmingham Biomedical Research Centre, Birmingham, United Kingdom. |
|---|
